|Clinical and Regulatory|
|Event Type:||Phase 3 Results|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|Disease and Treatment|
|Treatment Name:||Zoptrex (zoptarelin doxorubicin)|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
|Co. Name:||Aeterna Zentaris|
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
Detailed Event Description from Company Announcement
CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the “Company”) today reconfirmed its commitment to LHRH-receptor targeted therapy and its expectation that the pivotal, phase 3 trial for Zoptrex™ (zoptarelin doxorubicin) in women with advanced, recurrent endometrial cancer, is expected to be completed in the third quarter of 2016. During the 2016 Annual Meeting of the American Society of Clinical Oncologists (“ASCO”), the Company also discussed its plans to develop Zoptrex™ for additional indications, based upon achieving a positive outcome in the current clinical program.